Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Payables (2016 - 2025)

Bio-Techne (TECH) has 16 years of Payables data on record, last reported at $26.3 million in Q4 2025.

  • For Q4 2025, Payables fell 20.69% year-over-year to $26.3 million; the TTM value through Dec 2025 reached $26.3 million, down 20.69%, while the annual FY2025 figure was $25.3 million, 33.34% down from the prior year.
  • Payables reached $26.3 million in Q4 2025 per TECH's latest filing, down from $30.2 million in the prior quarter.
  • Across five years, Payables topped out at $38.0 million in Q2 2024 and bottomed at $24.1 million in Q4 2022.
  • Average Payables over 5 years is $29.2 million, with a median of $29.1 million recorded in 2021.
  • Peak YoY movement for Payables: surged 47.86% in 2024, then plummeted 33.34% in 2025.
  • A 5-year view of Payables shows it stood at $26.8 million in 2021, then fell by 9.93% to $24.1 million in 2022, then surged by 30.76% to $31.5 million in 2023, then increased by 5.1% to $33.1 million in 2024, then decreased by 20.69% to $26.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $26.3 million in Q4 2025, $30.2 million in Q3 2025, and $25.3 million in Q2 2025.